Syntheses, structures and antimicrobial activities of various metal complexes of hinokitiol

Lipophilic Fe(III)-Complex with Potent Broad-Spectrum Anticancer Activity and Ability to Overcome Pt Resistance in A2780cis Cancer Cells

Although iron is essential for all forms of life, it is also potentially toxic to cells as the increased and unregulated iron uptake can catalyze the Fenton reaction to produce reactive oxygen species (ROS), leading to lipid peroxidation of membranes, oxidation of proteins, cleavage of DNA and even activation of apoptotic cell death pathways. We demonstrate that Fe(hinok)₃ (hinok = 2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one), a neutral Fe(III) complex with high lipophilicity is capable of bypassing the regulation of iron trafficking to disrupt cellular iron homeostasis; thus, harnessing remarkable anticancer activity against a panel of five different cell lines, including Pt-sensitive ovarian cancer cells (A2780; IC₅₀ = 2.05 ± 0.90 μM or 1.20 μg/mL), Pt-resistant ovarian cancer cells (A2780cis; IC₅₀ = 0.92 ± 0.73 μM or 0.50 μg/mL), ovarian cancer cells (SKOV-3; IC₅₀ = 1.23 ± 0.01 μM or 0.67 μg/mL), breast cancer cells (MDA-MB-231; IC₅₀ = 3.83 ± 0.12 μM or 2.0 μg/mL) and lung cancer cells (A549; IC₅₀ = 1.50 ± 0.32 μM or 0.82 μg/mL). Of great significance is that Fe(hinok)₃ exhibits unusual selectivity toward the normal HEK293 cells and the ability to overcome the Pt resistance in the Pt-resistant mutant ovarian cancer cells of A2780cis.

Hinokitiol-iron complex is a ferroptosis inducer to inhibit triple-negative breast tumor growth

BACKGROUND

Ferroptosis is a unique cell death, dependent on iron and phospholipid peroxidation, involved in massive processes of physiopathology. Tremendous attention has been caught in oncology, particularly for those therapy-resistant cancers in the mesenchymal state prone to metastasis due to their exquisite vulnerability to ferroptosis. Therefore, a therapeutical ferroptosis inducer is now underway to be exploited.

RESULTS

A natural compound, hinokitiol (hino), has been considered to be an iron chelator. We have a novel finding that hino complexed with iron to form Fe(hino)3 can function as a ferroptosis inducer in vitro. The efficiency, compared with the same concentration of iron, increases nearly 1000 folds. Other iron chelators, ferroptosis inhibitors, or antioxidants can inhibit Fe(hino)3-induced ferroptosis. The complex Fe(hino)3 efficacy is further confirmed in orthotopic triple-negative breast cancer (TNBC) tumor models that Fe(hino)3 significantly boosted lipid peroxidation to induce ferroptosis and significantly reduced the sizes of TNBC cell-derived tumors. The drug's safety was also evaluated, and no detrimental side effects were found with the tested dosage.

CONCLUSIONS

When entering cells, the chelated iron by hinokitiol as a complex Fe(hino)3 is proposed to be redox-active to vigorously promote the production of free radicals via the Fenton reaction. Thus, Fe(hino)3 is a ferroptosis inducer and, therapeutically, exhibits anti-TNBC activity.

Hinokitiol, an Advanced Bidentate Ligand for Uranyl Decorporation

Despite the critical role actinide decorporation agents play in the emergency treatment of people in nuclear accidents and other scenarios that may cause internal contamination of actinides, new ligands have seldom been reported in recent decades because the current inventory has been limited to only a handful of functional groups. Therefore, new functional groups are always being urgently sought for the introduction of advanced actinide decorporation agents. Herein, a tropolone derivative, 2-hydroxy-6-(propan-2-yl)cyclohepta-2,4,6-trien-1-one (Hinokitiol or Hino), is proposed to be a promising candidate for this purpose by virtue of its well-demonstrated high membrane permeability and high affinity for metal ions. The coordination stoichiometry of Hino with uranyl is demonstrated to be 3:1 both in an aqueous solution (pH 7.4) and in the solid state. The results of a liquid-liquid extraction experiment further show that Hino exhibits strong chelating ability and selectivity toward uranyl over biological essential metal ions (i.e., Mn²⁺, Zn²⁺, Co²⁺, and Ni²⁺) with an extraction efficiency of >90.0%. The in vivo uranyl removal efficacies of Hino in kidneys and bone of mice are demonstrated to be 67.0% and 32.3%, respectively. On the basis of the observations described above, it is highly possible that further modification of Hino will lead to a large family of multidentate agents with enhanced uranyl decorporation ability.

Harnessing the toxicity of dysregulated iron uptake for killing Staphylococcus aureus: reality or mirage?

Iron is essential for all forms of life including pathogenic bacteria. However, iron is also a double-edged sword in biology, as increase of iron uptake can result in reactive oxygen species (ROS)-triggered cell death from the iron-catalyzed Fenton reaction. In this study, we demonstrate that iron-hinokitiol, Fe(hinok)₃, a neutral Fe(III) complex formed with the naturally occurring metal chelator hinokitiol; (2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one) can harness the clear ability, due to its high lipophilicity and the nonpolar nature, to penetrate the cell membrane of Staphylococcus aureus (SA) and exhibit potent antimicrobial activity that is enhanced by approximately 10 000 times as compared with hinokitiol itself. Additionally, this Fe(III) complex shows a strong ability to inhibit biofilm formation. More importantly, the development of resistance in SA toward this complex is considerably hampered in comparison with that toward ciprofloxacin. The in vivo evaluation of antimicrobial efficacy in the murine model of skin wound infection by SA confirms that the treatment with a single dose of this complex can reduce the bacterial burden by 83%, demonstrating the therapeutic potential of Fe(hinok)₃ in treating skin and soft tissue infections.

Thallium(I) Tropolonates: Synthesis, Structure, Spectral Characteristics, and Antimicrobial Activity Compared to Lead(II) and Bismuth(III) Analogues

Synthesis, single-crystal X-ray determination diffraction and FT-IR, NMR (¹H, ¹³C, ¹⁹F and ²⁰⁵Tl), UV–vis, and luminescence spectra characteristics were described for series of thallium(I) compounds: thallium(I) triflate (Tl(OTf)), 1:1 co-crystals of thallium(I) triflate and tropolone (Htrop), Tl(OTf)·Htrop, as well as simple thallium(I) chelates: Tl(trop) (1), Tl(5-metrop) (2), Tl(hino) (3), with Htrop, 5-methyltropolone (5-meHtrop), 4-isopropyltropolone (hinokitiol, Hhino), respectively, and additionally more complex {Tl@[Tl(hino)]₆}(OTf) (4) compound. Comparison of their antimicrobial activity with selected lead(II) and bismuth(III) analogs and free ligands showed that only bismuth(III) complexes demonstrated significant antimicrobial activity, from two- to fivefold larger than the free ligands.

Separation of Isomers and Mechanisms of Inversion of Stereochemistry of Group 9 d6 Tris-Chelate Complexes of Hinokitiol

Tris-chelate complexes of Co(III), Rh(III), and Ir(III) with 4-isopropyltropolone (hinokitiol or β-thujaplicin) form by the substitution of carbonate and chloride ligands from group 9 trivalent metal salts. The new complexes are neutral, are readily soluble in most organic solvents, and are brightly colored with strong charge transfer bands. The fac isomers of Co(hino)₃ and Rh(hino)₃ were isolated from the mixture by fractional recrystallization from ethanol. The remaining mixtures were respectively enriched by 5:3 and 4.4:3 for the mer isomer. The ¹H NMR data show that the complexes exhibit remarkable stereochemical lability, which is unusual for diamagnetic d⁶ group 9 metals, with rotational barriers of 14.2 and 18.2 kcal/mol found for the inversion of stereochemistry of Co(hino)₃ and Rh(hino)₃. The low activation barriers, as well as the analysis of some key structural parameters, suggest that the inversion of stereochemistry occurs via a trigonal-twist (Bailar) mechanism. Facile substitution of a single hinokitiol ligand in the cobalt complex with ethylenediamine to form [Co(en)(hino)₂]Cl also indicates that the tris-chelates are substitutionally and configurationally labile.

New heterobimetallic ferrocenyl derivatives: Evaluation of their potential as prospective agents against trypanosomatid parasites and Mycobacterium tuberculosis

Searching for prospective agents against infectious diseases, four new ferrocenyl derivatives, [M(L)(dppf)4](PF₆), with M = Pd(II) or Pt(II), dppf = 1,1'-bis(dipheny1phosphino) ferrocene and HL = tropolone (HTrop) or hinokitiol (HHino), were synthesized and characterized. Complexes and ligands were evaluated against the bloodstream form of T. brucei, L. infantum amastigotes, M. tuberculosis (MTB) sensitive strain and MTB clinical isolates. Complexes showed a significant increase of the anti-T. brucei activity with respect to the free ligands (>28- and >46-fold for Trop and 6- and 22-fold for Hino coordinated to Pt-dppf and Pd-dppf, respectively), yielding IC₅₀ values < 5 μM. The complexes proved to be more potent than the antitrypanosomal drug Nifurtimox. The new ferrocenyl derivatives were more selective towards the parasite than the free ligands. The Pt compounds were less toxic on J774 murine macrophages (mammalian cell model), than the Pd ones, showing selectivity index values (SI = IC₅₀ murine macrophage/IC₅₀T. brucei) up to 23. Generation of the {M-dppf} compounds lead to a slightly positive impact on the anti-leishmanial potency. Although the ferrocenyl derivatives were more active on sensitive MTB than the free ligands (MIC₉₀ = 9.88-14.73 μM), they showed low selectivity towards the pathogen. Related to the mechanism of action, the antiparasitic effect cannot be ascribed to an interference of the compounds with the thiol-redox homeostasis of the pathogen. Fluorescence measurements pointed at DNA as a probable target of the new compounds. [Pt(Trop)(dppf)](PF₆) and [Pt(Hino)(dppf)](PF₆) could be considered prospective anti-T. brucei agents that deserve further research.

Cerium Tetrakis(tropolonate) and Cerium Tetrakis(acetylacetonate) Are Not Diamagnetic but Temperature-Independent Paramagnets

A new synthesis of cerium tetrakis(tropolonate), Ce(trop)₄, where trop is deprotonated 2-hydroxy-2,4,6-cycloheptatrienone) or Ce(O₂C₇H₅)₄, is developed that results in dark-purple crystals whose X-ray crystal structure shows that the geometry of the eight-coordinate compound closely resembles a D_{2 d} dodecahedron, based on shape parameters. The magnetic susceptibility as a function of the temperature (4-300 K) shows that it is a temperature-independent paramagnet, χ = 1.2(3) × 10^-4 emu/mol, and the L_III-edge X-ray absorption near-edge structure spectrum shows that the molecule is multiconfigurational, comprised of a f¹:f⁰ configuration mixture in a 50:50 ratio. Ce(acac)₄ and Ce(tmtaa)₂ (where acac is acetylacetonate and tmtaaH₂ is tetramethyldibenzotetraaza[14]annulene) have similar physical properties, as does the solid-state compound CeO₂. The concept is advanced that trop^-, acac^-, tmtaa^2-, cot^2-, and O^2- are redox-active ligands that function as electron donors, rendering the classification of these compounds according to their oxidation numbers misleading because their magnetic susceptibilities, χ, are positive and their effective magnetic moments, μ_eff, lie in the range of 0.1-0.7 μ_B at 300 K.

Restored iron transport by a small molecule promotes absorption and hemoglobinization in animals

Multiple human diseases ensue from a hereditary or acquired deficiency of iron-transporting protein function that diminishes transmembrane iron flux in distinct sites and directions. Because other iron-transport proteins remain active, labile iron gradients build up across the corresponding protein-deficient membranes. Here we report that a small-molecule natural product, hinokitiol, can harness such gradients to restore iron transport into, within, and/or out of cells. The same compound promotes gut iron absorption in DMT1-deficient rats and ferroportin-deficient mice, as well as hemoglobinization in DMT1- and mitoferrin-deficient zebrafish. These findings illuminate a general mechanistic framework for small molecule-mediated site- and direction-selective restoration of iron transport. They also suggest that small molecules that partially mimic the function of missing protein transporters of iron, and possibly other ions, may have potential in treating human diseases.

Zn(ii) and Cu(ii) complexes containing bioactive O,O-chelated ligands: homoleptic and heteroleptic metal-based biomolecules

Zn(ii) or Cu(ii) highly stable complexes with chelated O,O-donor ligands from natural extractions give rise to drug delivery systems, new biologically active complexes and potential diagnostic agents due to their intrinsic spectroscopic properties.

A urea adduct of bis(hinokitiolato)copper(II)

Bis(μ(2)-3-isopropyl-7-oxocyclohepta-1,3,5-trien-1-olato)bis[(3-isopropyl-7-oxocyclohepta-1,3,5-trien-1-olato)copper(II)]-urea-acetone (1/6/2), [Cu(2)(C(10)H(11)O(2))(4)]·6CH(4)N(2)O·2C(3)H(6)O, where 3-isopropyl-7-oxocyclohepta-1,3,5-trien-1-olate is the systematic name for the hinokitiolate anion, contains three novel structural features. First, it contains a bis(hinokitiolato)copper(II) dimer, [Cu(hino)(2)](2), unlike any other, demonstrating that linkage isomerism is another avenue by which Cu(hino)(2) can transmute from one form to another. Second, [Cu(hino)(2)](2) is hydrogen bonded to two urea molecules, indicating that hydrogen bonding cannot yet be discounted from any proposed mechanism of action for the antimicrobial and antiviral properties of bis(hinokitiolato)copper(II). Finally, corrugated urea layers crosslinked by [Cu(hino)(2)](2) dimers are observed, suggesting that a new family of host-guest materials, i.e. metallo-urea clathrates, exists to challenge our understanding of crystal engineering and crystal growth and design. Selected details of the structure are that the [Cu(hino)(2)](2) dimers possess crystallographic inversion symmetry, the Cu atoms have square-pyramidal coordination geometries, the basal Cu-O bonds are in the range 1.916 (2)-1.931 (2) Å, the apical Cu-O bond length is 2.582 (2) Å, the hinokitiolate bite angles are in the range 83.41 (7)-83.96 (8)°, the urea-Cu(hino)(2) interactions have an R(2)(2)(8) motif, and the urea layers result from the close packing of R(8)(6)(28) 'butterflies' and R(8)(6)(24) 'strips of tape'.

Bis(hinokitiolato)copper(II): modification (III)

Bis(hinokitiolato)copper(II), Cu(hino)(2), exhibits both antibacterial and antiviral properties, and has been previously shown to exist in two modifications. A third modification has now been confirmed, namely tetrakis(mu(2)-3-isopropyl-7-oxocyclohepta-1,3,5-trien-1-olato)bis(3-isopropyl-7-oxocyclohepta-1,3,5-trien-1-olato)tricopper(II)-bis(mu(2)-3-isopropyl-7-oxocyclohepta-1,3,5-trien-1-olato)bis[(3-isopropyl-7-oxocyclohepta-1,3,5-trien-1-olato)copper(II)] (1/1), [Cu(C(10)H(11)O(2))(2)](3).[Cu(C(10)H(11)O(2))(2)](2), where 3-isopropyl-7-oxocyclohepta-1,3,5-trien-1-olate is the systematic name for the hinokitiolate anion. This new modification is composed of discrete [cis-Cu(hino)(2)](2)[trans-Cu(hino)(2)] trimers and [cis-Cu(hino)(2)](2) dimers. The Cu atoms are bridged by mu(2)-O atoms from the hinokitiolate ligands to give distorted square-pyramidal and distorted octahedral Cu(II) coordination environments. Hence, the Cu(II) environments are CuO(5)/CuO(6)/CuO(5) for the trimer and CuO(5)/CuO(5) for the dimer. Each trimer and dimer has crystallographically imposed inversion symmetry. The trimer has never been observed before, the dimer has been seen only once before, and the combination of the two together in the same lattice is unprecedented. The CuO(5) cores exhibit four strong basal Cu-O bonds [1.915 (2)-1.931 (2) A] and one weak apical Cu-O bond [2.652 (2)-2.658 (2) A]. The CuO(6) core exhibits four strong equatorial Cu-O bonds [1.922 (2)-1.929 (2) A] and two very weak axial Cu-O bonds [2.911 (3) A]. The bite angles for the chelating hinokitiolate ligands range from 83.13 (11) to 83.90 (10) degrees .